DBRC
AQST icon

D.B. Root & Company’s Aquestive Therapeutics AQST Stock Holding History

D.B. Root & Company’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-11,450
Closed -$23.1K – 178
2023
Q4 		$23.1K Sell
11,450
-1,500
-12% -$2.65K 0.01% 164
2023
Q3 		$19.8K Hold
12,950
– – 0.01% 164
2023
Q2 		$21.4K Buy
12,950
+450
+4% +$814 0.01% 168
2023
Q1 		$14.3K Hold
12,500
– – 0.01% 165
2022
Q4 		$11.3K Hold
12,500
– – ﹤0.01% 157
2022
Q3 		$14K Hold
12,500
– – 0.01% 156
2022
Q2 		$7K Buy
+12,500
New +$16.6K ﹤0.01% 166

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

D.B. Root & Company's AQST Position: Q1 2024 in Review

D.B. Root & Company sold out of Aquestive Therapeutics (AQST) in Q1 2024, closing a stake of 11,450 shares — an estimated $23.1K sold.

D.B. Root & Company first reported a position in AQST in Q2 2022 and held it in 7 quarters. The position peaked at $23.1K in Q4 2023. 97 funds tracked by Wall St. Rank hold AQST as of Q1 2024.

  • D.B. Root & Company reported no remaining Aquestive Therapeutics position as of Q1 2024 after selling out during the quarter.
  • D.B. Root & Company sold 11,450 Aquestive Therapeutics shares in Q1 2024, an estimated $23.1K.
  • D.B. Root & Company first reported a position in Aquestive Therapeutics in Q2 2022 and held it in 7 quarters.
  • D.B. Root & Company's Aquestive Therapeutics position peaked at $23.1K in Q4 2023.
  • 97 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2024.

Based on D.B. Root & Company's 13F filing for Q1 2024, filed 17 Apr 2024.